| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2017: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
In patients with drug-resistant heart failure, it was found that the increase in fractional excretion of potassium (FEK) after tolvaptan administration was significantly correlated with poor prognosis. As tolvaptan is a drug that, unlike other natriuretic drugs, has no effect on potassium excretion, increase in potassium excretion rate in the kidney after tolvaptan administration is thought to reflect renal blood flow reduction or activation of renin / angiotensin / aldosterone system. FEK was considered to be a convenient and useful indicator that it can find unexpectedly excessive free water removal at an early stage after tolvaptan administration.
|
